Effect of hyperbaric oxygen on oxygen uptake and measurements in the blood and tissues in a normobaric environment

A N H Hodges, S Delaney, J M Lecomte, V J Lacroix, D L Montgomery

Objective: To examine venous partial pressure of oxygen (PvO2), transcutaneous oxygen tension (tcPO2), and VO2MAX in a normobaric environment after a single hyperbaric oxygen (HBO2) treatment.

Methods: This was a prospective study of conditions after the intervention compared with baseline. The participants were 10 moderately trained (VO2MAX = 57.6 ml/kg/min) men. Two HBO2 treatments consisting of breathing 95% oxygen at 2.5 atmospheres absolute (ATA) for 90 minutes were administered on non-consecutive days. Baseline testing included measures of VO2MAX, tcPO2, and anthropometry. At 6.0 (1.0) minutes after the first HBO2 treatment, a VO2MAX test was performed. After the second HBO2 treatment, leg and chest tcPO2 and PvO2 were monitored for 60 minutes.

Results: VO2MAX, running time, and peak blood lactate were not altered after the HBO2 treatment. Leg tcPO2 was lower (p = 0.003) and chest tcPO2 was unchanged after the HBO2 treatment compared with baseline values. PvO2 was significantly (p<0.001) lower in the first three minutes after treatment than subsequent values, but no other differences were found.

Conclusions: A single HBO2 treatment at 2.5 ATA for 90 minutes does not raise PVO2, tcPO2, or VO2MAX in a normobaric, normoxic environment.

In recent years some professional and college athletic teams have used hyperbaric oxygen (HBO2) to treat sports injuries, to speed recovery after exercise, and as an ergogenic aid to enhance performance. Because of the importance of oxygen in the aerobic energy system, professional athletes sometimes receive HBO2 before participation in their sport in the belief that subsequent performance will be improved. HBO2 therapy is defined as a medical treatment in which the patient breathes 100% oxygen intermittently while inside a chamber at a pressure greater than 1 atmosphere absolute (ATA). The Undersea and Hyperbaric Medical Society currently approves 13 medical indications for treatment with HBO2.

Physiologists have long debated whether oxygen delivery or use by the skeletal muscles is the limiting factor for VO2MAX. Potential physiological factors limiting VO2MAX include: (a) pulmonary diffusion capacity for O2; (b) maximal cardiac output; (c) the peripheral circulation; (d) the metabolic capacity of skeletal muscle. Physiologists believe that the capacity of the central cardiovascular system to transport oxygen to the tissues is the principal determinant of VO2MAX. This concept has been used to justify HBO2 treatments to enhance the availability of oxygen in an attempt to increase maximal aerobic performance. Also, oxygen stored in the tissues after an HBO2 treatment may be available to working muscles.

Our reasons for this study are the contrary findings in the research literature and the observation that the athletic community has used HBO2 before sport performance. Under pressure, oxygen dissolves in all body fluids. For HBO2 to be beneficial, increased oxygen must be stored during the treatment and remain raised on return to a normobaric, normoxic environment. Previous studies have not examined the blood or tissues to determine if these compartments would be additional sources of oxygen available to the mitochondria during maximal exercise. Because of potential misuse by the athletic community, there is a need to establish if there are benefits in using HBO2 as an ergogenic aid. This study examines the ergogenic potential of HBO2. We hypothesised that: (a) venous partial pressure of oxygen (PvO2) and/or transcutaneous oxygen tension (tcPO2) would be unchanged after a single HBO2 treatment in a normobaric environment; (b) VO2MAX would be similar after a single HBO2 treatment in a normobaric environment.

METHODS

Subjects

The subjects were 10 trained (VO2MAX = 57.6 (6.2) ml/kg/min) male volunteers (Table 1). They were examined by a doctor and were excluded if contraindications to HBO2 treatment were evident (recent thoracic surgery, repeated ear infections, asthma, cataracts, diabetes, receiving anticonvulsant medication, hereditary spherocytosis, and recent upper respiratory tract infections). All experimental procedures were evaluated and approved by the McGill University Faculty of Medicine institutional review board. Subjects gave written consent to participate after the design and risks of the study had been described to them.

Experimental design

Subjects underwent tests on three non-consecutive days within a two week period. Baseline testing on day 1 included assessment of physical characteristics, tcPO2 during normoxic and hyperoxic breathing, and measurement of VO2MAX. Testing on day 2 included a 90 minute HBO2 treatment followed by a VO2MAX test. The time delay from exiting the hyperbaric chamber to the start of the VO2MAX test was 6.0 (1.0) minutes. On day 3, subjects received a 90 minute HBO2 treatment.

Abbreviations: HBO2, hyperbaric oxygen; PvO2, venous partial pressure of oxygen; tcPO2, transcutaneous oxygen tension; VO2max, maximum oxygen consumption.
treatment followed by nine \( P_{\text{vO}_2} \) samples and \( tc\text{PO}_2 \) measurements for 60 minutes.

**Hyperbaric oxygen protocol**

Figures 1 and 2 illustrate the HBO\(_2\) chamber and protocol. The HBO\(_2\) treatment was administered in a Sigma Plus monoplace hyperbaric chamber (Perry Baromedical Corporation, Riviera, Florida, USA) under the supervision of a certified chamber operator at the Cleghorn Hyperbaric Laboratory, McGill University. It took about 10 minutes to pressurise the chamber to 2.5 ATA with 95% oxygen. At 25 and 55 minutes into the 90 minute treatment, subjects were given a five minute air break through an oronasal mask to reduce the risk of oxygen toxicity. After 90 minutes, the chamber was decompressed from 2.5 to 1.0 ATA in about eight minutes.

Under normal sea level conditions, barometric pressure is 1 ATA or 760 mm Hg, and oxygen content in the air is 20.9%. In these conditions the \( P_{\text{aO}_2} \) is 100 mm Hg. During our HBO\(_2\) treatment, the combination of increased pressure (2.5 ATA) and increased oxygen concentration (95%) results in additional oxygen dissolved in plasma. During the hyperbaric treatment at these conditions the \( P_{\text{aO}_2} \) is predicted to be:

\[
P_{\text{aO}_2} = ((\text{PBTPS} \times F_{\text{O}_2}) - (P_{\text{CO}_2}/R)) - (40 \text{ mm Hg/0.82})
\]

\[
P_{\text{aO}_2} = ((2.5 \text{ ATA} \times 760) - (47 \text{ mm Hg}) \times 0.95) - (40 \text{ mm Hg}) = 1853 - 49 = 1804 \text{ mm Hg}
\]

where PBTPS = pressure at body temperature pressure saturated (mm Hg), \( F_{\text{O}_2} \) = fraction of oxygen in inspired air (%), \( P_{\text{CO}_2} \) = partial pressure of \( \text{CO}_2 \) in arterial blood (mm Hg), and \( R \) = respiratory quotient.

**Exercise test procedure**

Before the exercise test, physical characteristics (height, weight, and body composition) were measured. Percentage body fat was estimated from skinfold measurements and the regression equation of Jackson and Pollock.\(^9\)

**tcPO\(_2\) measurement**

\( tc\text{PO}_2 \) was measured at two sites: chest (second intracostal) and leg (mid-thigh over the rectus femoris). The sites were prepared by removal of hair, cleaning with alcohol, and denuding the skin by repeated application and removal of adhesive tape.\(^{10,11} \) A calibrated TCM 30 Transcutaneous Po\(_2\) Monitoring System (Radiometer, Copenhagen, Denmark) was used to measure \( tc\text{PO}_2 \) continuously. The electrodes were warmed to 45C as recommended for use in hyperbaric operations.\(^{11,12} \) There was a lag of about 10 minutes after application of the electrodes before stable values were achieved. Values were recorded every minute for 60 minutes. The baseline \( tc\text{PO}_2 \) assessment included a 20 minute oxygen challenge in which the subjects breathed 100% oxygen through an oronasal mask from minute 20 to minute 40 to demonstrate their \( tc\text{PO}_2 \) responsiveness to high concentrations of oxygen.

**\( P_{\text{vO}_2} \) measurement**

When each subject left the hyperbaric chamber on day 3, a 14 gauge intravenous catheter was inserted into an antecubital vein. The line was kept patent between samples with 5% dextrose solution (IV\(_{D5W}\)). Blood samples (3–5 ml) were drawn 3, 5, 10, 15, 20, 30, 40, 50, and 60 minutes after the subject had left the chamber. To ensure blood samples were not contaminated with IV\(_{D5W}\) solution, 5 ml blood was drawn and discarded before every blood sample was collected. Samples were immediately aspirated into a

---

**Table 1** Physical characteristics of the subjects (\( n = 10 \))

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>25.7 (5.5)</td>
<td>20–38</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>179.7 (7.5)</td>
<td>165.0–194.9</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>76.4 (4.1)</td>
<td>70.9–82.3</td>
</tr>
<tr>
<td>Percentage fat</td>
<td>10.2 (2.0)</td>
<td>5.5–17.4</td>
</tr>
<tr>
<td>( VO_{2\text{MAX}} ) (ml/kg/min)</td>
<td>57.6 (6.2)</td>
<td>47.5–67.1</td>
</tr>
</tbody>
</table>

---

**Figure 1** Hyperbaric oxygen monoplace chamber.

**Figure 2** Hyperbaric oxygen protocol. ATA, Atmospheres absolute.

\( VO_{2\text{MAX}} \) was measured on a Quinton Q65 Series 90 treadmill (Quinton Instruments, Seattle, Washington, USA). Subjects began an incremental test at 5 mph (134 m/min) and 5% grade with speed increased by 0.5 mph (13.4 m/min) every minute until volitional exhaustion. Expired gases were collected with \( V_{\text{E}}, \) \( V_{\text{O}_2}, \) and \( V_{\text{CO}_2} \) averaged every 20 seconds using a SensorMedics 2900 Metabolic Measurement Cart (SensorMedics, Yorba Linda, California, USA). Subjects were verbally encouraged to continue exercising until volitional exhaustion. Criteria for reaching \( VO_{2\text{MAX}} \) were attainment of age predicted heart rate maximum, a respiratory exchange ratio of 1.10, or a plateau in \( V_{\text{O}_2} \) with increased workload. \( VO_{2\text{MAX}} \) was calculated by averaging the highest values over one minute. Heart rate was measured using a Polar Accurex Heart Rate Monitor (Polar Electro, Kempele, Finland) and averaged every five seconds. Four minutes after the \( VO_{2\text{MAX}} \) test, a finger prick blood sample was taken to determine peak blood lactate concentration. The blood samples were analysed with an Accusport Portable Lactate Analyzer (Behringer Mannheim, Mannheim, Germany).

---

![Figure 1](image1.png)

![Figure 2](image2.png)
Radiometer ABL5 blood analyser, which was calibrated with known samples provided by the manufacturer. Every 30 minutes, the blood analyser performed a barometric pressure and a 1 point calibration of the $P\,O_2$ electrode using gas of 19.8% $O_2$. Every two hours the blood analyser performed a 2 point calibration of the $P\,O_2$ electrode using gases of 0% and 19.8% $O_2$.

With regard to blood sampling, our preference was to obtain arterial $Pao_2$ ($PaO_2$) measurements because it is unclear how long $Pao_2$ remains raised after an HBO2 treatment. The ethics institutional review board did not approve arterial sampling for this study, and requested that an intravenous catheter be used to obtain blood samples.

**Statistical analysis**

Paired $t$ tests were used to compare baseline conditions with those after treatment for VO2MAX and peak blood lactate data. A one way repeated measures analysis of variance was used to compare $PvO_2$ data for the two conditions. A two way repeated measures analysis of variance was used to compare tcPO2 data at two sites (chest and leg) and two conditions (baseline and after HBO2). Analysis of variance was followed by post hoc comparisons using Tukey’s HSD (honestly significant difference) test. For all statistical analyses, was set at $p<0.05$.

**RESULTS**

Table 2 shows the exercise test results. No significant differences were found for VO2MAX or peak blood lactate concentration between the baseline condition and after HBO2 treatment. The mean (SD) VO2MAX values were 57.6 (6.2) and 57.3 (5.8) ml/kg/min in the two conditions. The time from exiting the chamber and initiation of the exercise test was 6.0 (1.0) minute. The HBO2 treatment did not enhance exercise performance, as run times were identical in both conditions (10.1 (1.9) min). Peak lactate concentrations were similar (8.9 (2.8) and 10.0 (1.9) mmol/l) in the two conditions.

Table 3 summarises and fig 3 illustrates the $PvO_2$ results. There was a significant change in $PvO_2$ over time ($F = 6.61$; df 8.40; $p<0.001$) after the HBO2 treatment, with a lower $PvO_2$ value at three minutes than at 5–60 minutes. The tourniquet on the upper arm was in place for about one minute before drawing of the initial blood sample. We attribute the significantly lower $PvO_2$ at three minutes to altered blood flow in the arm. The $PvO_2$ data suggest that there was no excess oxygen circulating in the blood after the HBO2 treatment.

Figure 4 summarises the tcPO2 data. In the baseline condition, the start of the oxygen challenge was at 20 minutes. The chest tcPO2 increased from about 80 to 290 mm Hg in about five minutes, and the leg tcPO2 increased from 70 to 230 mm Hg in the same time frame. Upon completion of the oxygen challenge at 40 minutes, both the chest and leg tcPO2 returned to baseline values within three minutes. After the HBO2 treatment, the leg tcPO2 was significantly ($F = 11.93$; df 1.18; $p = 0.003$) lower than the baseline values, with a difference of 14 mm Hg. In contrast, the chest tcPO2 values were similar at baseline and after HBO2 treatment.

**DISCUSSION**

Intermittent HBO2 treatments have been used to speed recovery of muscle strength after exercise induced injury. Quadriceps muscle soreness was induced by eccentric exercise. HBO2 treatments improved recovery of eccentric strength compared with placebo treatments. The effect of a
Effect of hyperbaric oxygen

A single HBO2 treatment at 2.5 ATA for 90 minutes does not raise VO2max in a normobaric, normoxic environment. Transcutaneous tissue and blood PO2 measurements after the HBO2 treatment support the statement that HBO2 does not have ergogenic benefits for the athletic community.

REFERENCES
2 Hampson NB, e, eds. Hyperbaric oxygen therapy: 1999 committee report. Kensington, MD: Undersea & Hyperbaric Medical Society, 1999

McGavock et al. examined the acute effects of a single HBO2 treatment on aerobic performance in a normobaric environment. Subjects (n = 12) performed four exercise-HBO2 conditions designated as: (a) control; (b) exercise-non-HBO2; (c) no exercise-HBO2; (d) exercise-HBO2. Exercise was a 90 minute run to produce fatigue. The HBO2 treatments were at 2.5 ATA for 90 minutes. At the end of each condition, aerobic performance was assessed using running economy tests and a VO2MAX test. The time between exiting the chamber and running on the treadmill averaged 40 minutes. Recovery was not enhanced after a single HBO2 treatment nor did it alter submaximal or maximal running performance.

Our findings support the results of Webster et al. and McGavock et al. Baseline conditions and those after HBO2 were similar for VO2MAX, treadmill running time, and peak blood lactate, indicating that the single HBO2 treatment was not ergogenic.

tcPO2 is a reliable assessment of oxygen available to tissues. It is traditionally used to predict if HBO2 treatment will be beneficial for wound healing and to maintain tissue oxygen values within an appropriate range. Chest tcPO2 values have been recorded at 1312 (112) mm Hg during a HBO2 treatment at 2.4 ATA. In our study, tcPO2 was used to assess oxygen levels in muscle tissue after the HBO2 treatment. It appears that the excess oxygen that is physically dissolved in plasma during HBO2 is rapidly consumed upon exiting the HBO2 chamber. Upon application of the tcPO2 electrode, it takes about 10 minutes to obtain a reliable value as the electrode warms the skin. In our study, 10 minutes after exiting the chamber tcPO2 values had returned to baseline and leg tcPO2 values were lower than baseline. The lower tcPO2 values in the leg may be attributed to vasoconstriction. It has been shown both in vivo and in vitro that blood flow is decreased when inspired PO2 increases above 500 mm Hg. The vasoconstrictive effect occurs in both arterial and venous vascular beds.

Sheffield presents normal values for blood and tissue O2 measured by blood gas analyser, mass spectrometer, tissue tonometer, implanted polarographic electrode, and tcPO2 at pressures of 1-3 ?ATA. Normal mean values for PO2 range from 36 to 40 mm Hg. Between 10 and 60 minutes after HBO2, our PO2 values ranged from 31.7 to 38.7 mm Hg indicating that there was no excess oxygen circulating in the blood. Banister data examined PaO2 and PacO2 after an HBO2 treatment in two subjects. The PaO2 and PacO2 remained unchanged. The time from the end of treatment to drawing blood samples was not stated. Our PO2 and tcPO2 data indicate that plasma and tissue oxygen levels are not raised after HBO2. After our HBO2 treatment, PO2 was relatively constant from 5 to 60 minutes. The only significant finding occurred at three minutes after treatment with a lower PO2 value. We attribute the significantly lower PO2 at three minutes to altered blood flow in the arm, as a tourniquet was placed on the upper arm for about one minute before drawing of the initial blood sample. The PO2 data suggest that there was no excess oxygen circulating in the blood after the HBO2 treatment. Tissue autoregulation reduces O2 levels upon return to a normobaric, normoxic environment.

In summary, the results of this study show that a single HBO2 treatment at 2.5 ATA for 90 minutes does not raise VO2MAX in a normobaric, normoxic environment. Oxygen measurements in the venous blood (PvO2) and in the tissues (tcPO2) provide new data to support the rationale that HBO2 treatments do not enhance performance. This message needs to be conveyed by doctors and sport scientists to the athletic community. Our findings support the work of Webster et al., McGavock et al., and the Undersea and Hyperbaric Medical Society statement that HBO2 does not have ergogenic properties.